UPDATE: Click here to order samples for your practice.

Bausch + Lomb is committed to helping
eligible patients save on LOTEMAX® SM

Most eligible insured patients may pay no more than*:

COMMERCIALLY INSURED
$25
MEDICARE PART D
$60

Discounted $75 co-pay available for eligible uninsured patients*.

*Terms, limitations and conditions apply. Most eligible commercially insured patients may pay no more than $25 co-pay for their first prescription and eligible refills, exclusively at Walgreens and other participating independent pharmacies. Please see www.bauschaccessprogram.com or www.lotemaxsmpartdcoupon.com for eligibility criteria and terms and conditions.

Commercial Patient Savings

To help eligible patients save, visit the link below to access web coupons or contact a sales representative to provide printed coupons in your office.

Access Patient Commercial Coupon

Coupons may be activated by calling 1-866-693-4880, texting BLSAVINGS to 24109, or visiting www.bauschaccessprogram.com. Text fees may apply.

The LOTEMAX® SM Part D Program savings for Medicare Part D patients

Access Patient PART D Coupon
  • ACTIVATE: Patients can activate the print coupon by calling 1-866-686-0130. Web coupon is automatically activated once patient agrees to statements on www.lotemaxsmpartdcoupon.com to download coupon.
  • REDEEM: Redeem the coupon card at a participating retail pharmacy with prescription and insurance card.
  • MAIL: Make sure patients sign and mail the prewritten letter, which notifies the health plan of their choice to use the benefits of this program. Healthcare plan address can be found on the Medicare provider card.

To help eligible patients save, visit the link above to access web coupons or contact a sales representative to provide printed coupons in your office.

Ensure your patients activate their
coupon prior to visiting the pharmacy.

INDICATION

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

IMPORTANT SAFETY INFORMATION
  • LOTEMAX® SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation.
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections.
  • Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.
  • Contact lenses should not be worn when the eyes are inflamed.
  • There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for LOTEMAX® SM.

LOTEMAX is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates. LSM.0128.USA.20
All information and materials on this site pertain to the U.S. only, unless otherwise indicated.
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

The information contained in this section of the site is intended for U.S. healthcare professionals only.

Click 'Confirm' if you are a U.S. healthcare professional.

Cancel Confirm